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Abstract
Background: During chronic inflammation, immune cells, notably Th17 cells, infiltrate the inflammatory site and
interact with local mesenchymal cells. Applied to rheumatoid arthritis (RA), the aim is to study the interactions
between synoviocytes and peripheral blood mononuclear cells (PBMC) with a focus on the Th17 pathway and to
identify a mechanism which leads to high IL-17 secretion with an interest on podoplanin.
Methods: PBMC from healthy donors and RA patients were co-cultured with RA synoviocytes during 48 h, in the
presence or not of phytohemagglutinin. An antibody against podoplanin was used in co-culture. Cytokine
production (IL-6, IL-1β and IL-17) was measured by ELISA and cell staining (CD3, CD4, IL-17 and podoplanin) by
flow cytometry.
Results: In control conditions, IL-6 and IL-1β production was increased in PBMC-synoviocyte co-culture compared
to PBMC alone (p = 0.02). No additional effect was observed with PBMC activation. Flow cytometry analysis showed
no difference in the percentage of Th17 cells in activated PBMC alone or with synoviocytes (p = 0.4), indicating that
Th17 differentiation requires only T cell activation. Conversely, IL-17 production was highly increased in co-cultures
with activated PBMC vs. activated PBMC alone (p = 0.002). Transwell experiments confirm that cell-cell contact was
critical for IL-17 secretion. The incubation of either PBMC or synoviocytes with an anti-podoplanin antibody
decreased IL-17 secretion by 60 % (p = 0.008).
Conclusions: Interactions between resting PBMC and synoviocytes are sufficient to induce IL-6 and IL-1β
production. Both PBMC activation and cell interactions are needed to induce a high IL-17 secretion. Podoplanin
contributes at the level of both lymphocytes and synoviocytes.
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Background
Interleukin-17 (IL-17) is a pro-inflammatory cytokine
mainly produced by Th17 cells and involved in several
chronic inflammatory diseases, such as psoriasis or
rheumatoid arthritis (RA) [1, 2]. Commonly, an associ-
ation is made between Th17 cells and the secretion of
IL-17, using intracellular staining of IL-17 as an equiva-
lent of actual demonstration of protein secretion. As
shown in one of our previous studies, IL-17-positive
cells acquire a plasma cell-like morphology under in
vitro activation, which is correlated with enhanced con-
centrations of secreted IL-17. Moreover, in sections of
inflamed tissue, IL-17+ cells have this plasma cell-like
morphology [3]. The connection between IL-17 intracel-
lular staining and IL-17 secretion thus remained to be
clarified.
During chronic inflammatory diseases, the recruitment
of activated immune cells, including Th17 cells, to the
site of disease, leads to interactions with local mesenchy-
mal cells and this promotes cell proliferation and the
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chronicity of inflammation [4–6]. These interactions
between bone marrow-derived or synovium-derived
mesenchymal cells and activated peripheral blood mono-
nuclear cells (PBMC) promote Th17 cell expansion [7].
Regarding the crucial role of cell–cell interactions in
pro-inflammatory cytokine production, a mechanism
remained to be identified. Among many options, podo-
planin (pdpn) was considered as a possible candidate, as
a molecule involved in cell–cell interactions. Indeed,
pdpn modulates IL-8 secretion during interactions be-
tween platelets and synoviocytes through its receptor
CLEC-2 on platelets [8]. Moreover, the pdpn pathway is
involved in different animal models of inflammatory dis-
eases [9, 10]; notably in a mouse model of RA, pdpn is
upregulated in Th17 cells compared to other Th cell
subsets [9]. Pdpn expression is also upregulated in RA
synovium and it might increase the migratory potential
of activated synoviocytes in RA [11]. These results lead
us to consider pdpn as a potential new mechanism in-
volved in the Th17 pathway during chronic inflammation.
The aim of this study was to clarify the difference be-
tween intracellular expression from IL-17 secretion and
to identify a mechanism which leads to high IL-17 secre-
tion during interactions between PBMC and synovio-
cytes, with a special interest in podoplanin.
Materials and methods
Samples
RA synoviocytes were obtained from synovial tissue of
RA patients undergoing joint surgery and who fulfilled
the American College of Rheumatology criteria for RA
[12]. Synovial tissue was minced into small pieces and
then adhered in 6-well plates in Dulbecco’s modified
Eagle’s medium (DMEM; Eurobio, Courtaboeuf, France)
supplemented with 10 % fetal bovine serum (FBS; Life
Technologies, Carlsbad, CA, USA), 2 mM L-glutamine
and 100 U/ml penicillin/streptomycin. Cells were main-
tained at 37 °C in a humidified 5 % carbon dioxide incu-
bator and used between passages 4 to 9. They are
fibroblast-like synoviocytes which express pdpn and
secrete IL-6 after stimulation by tumor necrosis factor
(TNF) [11, 13]. PBMC from healthy donors or RA
patients were isolated by Ficoll-Hypaque (Eurobio,
Courtaboeuf, France) density-gradient centrifugation.
Adipose-derived stem cells (ASC) and human umbilical
vein endothelial cells (HUVEC) were used as control cells.
T cell cloning procedure
To obtain CD4+ T cell clones, CD4+ T cells were iso-
lated from peripheral blood mononuclear cells (PBMC)
of healthy donors by immunomagnetic cell separation
(Miltenyi Biotech, Bergisch Gladbach, Germany) and
further divided into the CD161 + CCR6+ and CD161-
CCR6- fractions by flow cytometry cell sorting
(FACSAria, BD Bioscience, Franklin Lakes, NJ, USA).
Both cell fractions obtained were seeded under limiting-
dilution conditions (0.5 cell/well) in round-bottom micro-
well plates, containing 105 irradiated (60 Gy [9000 rad])
allogeneic peripheral blood mononuclear cells as feeder
cells, 1 % phytohemagglutinin (PHA; vol/vol), and recom-
binant human IL-2 (50 U/mL). Blasts were expanded in
the presence of feeder cells (105 cells/well) plus IL-2 (50
U/mL). T cell clones were obtained and evaluated for their
cytokine production activity (interferon [IFN]-γ, and IL-
17) by flow cytometry after stimulation with PMA plus
ionomycin, as previously described [14, 15]. T cell clones
producing IL-17 alone were classified as Th17. Production
of cytokines by each clone was arbitrarily considered as
significant when the proportion of producing T cell blasts
was >20 %. Th17 clones obtained from the CD161 +
CCR6+ fraction were selected and further expanded in the
presence of feeder cells plus IL-2 until they reached the
number of approximately 106 blasts/clone, then they were
transferred in 24-well plates and maintained in culture in
the presence of IL-2 (50 U/mL).
Co-culture assays
Co-culture was initiated by seeding RA synoviocytes,
ASC or HUVEC overnight in 96-well plates at a density
of 2 × 104 cells/well in RPMI 1640 medium (Eurobio,
Courtaboeuf, France) supplemented with 10 % human
AB serum, 2 mM L-glutamine and 100 U/ml penicillin/
streptomycin (complete RPMI). The next day, PBMC
(1 × 105 cells/well) or Th17 clones (2 × 104 cells/well)
were seeded in complete RPMI corresponding to 5:1
ratio or 1:1 ratio, respectively, in the presence or absence
of phytohemagglutinin (PHA, 5 μg/ml). After 48 h,
supernatants and cells were collected for analysis.
Transwell assay
RA synoviocytes were seeded in 24-well plates at a dens-
ity of 1 × 105 cells/well in complete RPMI. After over-
night incubation, PBMC were added directly on top of
synoviocytes or in a cell culture insert (0.4 μm pore size)
at a concentration of 5 × 105 cells/well, in the presence
or absence of PHA (5 μg/ml). After 48 h, supernatants
and PBMC were recovered for analysis.
Cell fixation
Synoviocytes or PBMC were fixed for 1 h, at 4 °C, in
phosphate-buffered saline (PBS) 0.01 % paraformalde-
hyde before co-culture.
Enzyme-linked immunosorbent assays (ELISA)
IL-17A, IL-6, and IL-1β productions were evaluated
from culture supernatants with commercially available
DuoSet ELISA kits, according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA).
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Flow cytometry
Allophycocyanin (APC), phycoerythrin (PE), PE-cyanine-
7 or eFluor 450-conjugated antibodies (eBiosciences, San
Diego, CA, USA) were used to stain cells. EFluor 450-
CD3 (48–0038), PE-Cy7-CD4 (25–0049) and PE-pdpn
(12–9381) were used for cell surface staining, according
to the manufacturer’s instructions. PBMC were fixed
and permeabilized for APC-IL-17A (17–7179) intracellu-
lar staining. Cells were incubated in cold PBS and cold
2 % paraformaldehyde in the dark during 1 h for fixation
step. For permeabilization, cells were incubated in PBS
with 0.2 % Tween at 37 °C for 15 min, before intracellu-
lar staining. Flow cytometry staining buffer from eBios-
ciences (San Diego, CA, USA) was used for staining
protocol. Analysis was done with the Kaluza software
(Beckman Coulter, Brea, CA, USA).
Monocyte contribution
To remove monocytes, PBMC were pre-incubated during
2 h at 37 °C. The percentage of removal monocytes by
adherence was verified with flow cytometry. This method
allowed removing at least 50 % of monocytes.
Inhibition of podoplanin
A dose–response curve was performed to determine the
concentration of purified anti-human podoplanin anti-
body (14–9381, eBiosciences, San Diego, CA, USA)
required for maximal inhibition. PBMC were pre-
incubated for 4 h with different concentrations of anti-
podoplanin (0, 1, 5, 10 and 20 μg/ml) before co-culture
assay. According to the results of dose–response curve,
all experiments studying podoplanin were realized with
anti-podoplanin at 5 μg/ml. A control antibody against
the BetV1 allergen with no effect in the assays was used
at the same concentration (anti-BetV1 Ab, Dendritics,
Lyon, France).
Small interfering RNA (siRNA)
A mixture of four small interfering RNA (siRNA)
provided as a single reagent (siGENOME human
SMARTPool siRNA) specific for podoplanin (M-017560-
01-0005) was purchased from Dharmacon, Lafayette,
CO, USA. RA synoviocytes were seeded at a density of
5 × 105 cells/12-well plate before transfection and used
at 80–90 % confluence. Cells were transfected with
control siRNAs (siCONTROL siRNA as a negative
control (mock) and siGLO peptidylpropyl isomerase B
(PPIB) (cyclophilin B) as a positive control) or target siR-
NAs (siGENOME SMARTPool pdpn siRNA) by nucleo-
fection (Amaxa Pharma, London, UK) according to the
manufacturer’s instructions (program U23; Human
Dermal Fibroblast Nucleofector kit). Dose– and time–
response experiments were performed to determine the
best time point and the best suitable concentration of
siRNA duplexes needed for efficacious RNA silencing.
Cells were nucleofected with 37.6, 100 or 376 nM of
pdpn siRNA (siPdpn), per 5 × 105 cells. Twenty-four
hours or 48 h post-transfection, RNA was extracted and
RT-PCR performed to detect the RNA silencing. The
best condition was at 100 nM, at 48 h, thus this condi-
tion was used for the presented experiments.
RNA extraction and real-time PCR
Total RNA of synoviocytes was extracted using the
RNeasy Mini Kit (Qiagen®, Hilden, Germany) and quan-
tified with the Quant-it kit assay (Invitrogen™ by Thermo
Fisher Scientific, Grand Island, NY, USA) following the
manufacturer’s instructions. cDNA was synthesized
using the QuantiTect reverse transcription kit (Qiagen®)
according to the manufacturer’s instructions. SYBR
green-based real-time qRT-PCRs were performed on the
CFX96 Real-Time PCR Detection System (BioRad,
Hercules, CA, USA) using the QuantiFast SYBR green
kit and QuantiTect primers (Qiagen®). Cycle threshold
values were normalized with respect to the endogenous
control gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). The relative expression of pdpn and PPIB
genes in the different conditions was determined using
the comparative threshold cycle method as described by
the manufacturer.
Statistical analysis
Statistical analyses for co-culture assays were performed
using two-way ANOVA. For transwell, monocytes and
podoplanin experiments a paired nonparametric Wilcoxon
test was used. All analyses were performed with GraphPad
Prism 6 software (GraphPad Software, San Diego, CA,
USA). p values less than or equal to 0.05 were considered
as significant.
Results
Interaction between RA synoviocytes and PBMC induces
IL-6 and IL-1β production
PBMC produce pro-inflammatory cytokines, such as IL-
6 and IL-1β, which are implicated in the Th17 differenti-
ation [16–18]. Resting PBMC alone produced IL-6 at
low levels and their activation by PHA had a modest
effect (1.4 ± 3.4 ng/ml vs. 13.4 ± 11.8 ng/ml, Fig. 1a). IL-
1β production was almost undetectable in control condi-
tion (7.2 ± 16.1 pg/ml, Fig. 1b), and PHA activation
highly increased its secretion (2630.1 ± 2397.3 pg/ml, p
= 0.03, Fig. 1b). Co-culture of resting PBMC and syno-
viocytes significantly increased IL-6 and IL-1β produc-
tion compared with PBMC alone (443.0 ± 240.7 ng/ml
vs. 1.4 ± 3.4 ng/ml; p = 0.0001 and 2794.4 ± 2862.2 pg/ml
vs. 7.2 ± 16.1 pg/ml; p = 0.02, respectively, Fig. 1). Activa-
tion of PBMC by PHA had no additional effect in co-
culture (Fig. 1). These results indicated that the cell–cell
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contact was sufficient to activate the pro-inflammatory
cytokine production. Furthermore, as PBMC and synovio-
cytes from different donors were used in the different ex-
periments, this resulted in heterogeneity of cytokine
production observed in Fig. 1.
To investigate the importance of cell–cell contact, a
transwell system was used. The insert had a pore size of
0.4 μm, which prevents direct cell–cell contact but
allows the exchange of soluble factors. In this transwell
system, IL-6 and IL-1β production was significantly
decreased compared to control (89.1 ± 58.6 ng/ml vs.
289.5 ± 130.9 ng/ml, p = 0.008 and 40.1 ± 46.3 pg/ml vs.
1488.9 ± 1505.2 pg/ml, p = 0.008, respectively, Fig. 1). A
significant decrease of IL-6 and IL-1β production in the
transwell system was also observed with T cell receptor
(TCR) activation by PHA, nevertheless with a tendency
to a lower effect than in the control condition. This con-
firmed that cell–cell contact was sufficient and required
to activate cells to produce pro-inflammatory cytokines.
Moreover, to reinforce this result, fixed synoviocytes were
used in co-cultures. In these conditions, the secretion of
IL-6 and IL-1β were also induced. Nevertheless, the pro-
duction was at least 50 % lower for IL-6, as synoviocytes
were fixed and the level of IL-1β produced mostly by
monocytes was slightly decreased (data not shown).
PBMC activation and cell interactions with synoviocytes
are needed for a high IL-17 secretion
Th17 cells have been identified as a major source of IL-
17 [19] and IL-6 and IL-1β, which are increased by cell
interactions (Fig. 1) that are critical for Th17 differenti-
ation [16–18]. The role of cell interactions on the IL-17
pathway was studied to distinguish the intracellular
staining from the secretion of IL-17 in medium. Flow
cytometry analysis showed that IL-17-positive cells were
observed in culture of PBMC alone or in co-culture with
synoviocytes. However, there was no difference in the
percentage of IL-17-positive T cells in resting PBMC
alone or cultured with synoviocytes (1.9 ± 1.7 % vs. 1.7 ±
1.6 %, respectively, Fig. 2a). The effect of PHA activation
was not significant but with a tendency to higher Th17
cells with PHA (PBMC alone: 1.9 ± 1.7 % vs. 3.1 ± 1.7 %;
co-culture: 1.7 ± 1.6 % vs. 3.9 ± 2.7 %, p = 0.06, Fig. 2a).
In addition, PHA activation also increased the percent-
age of IL-17+ cells among the CD3 + CD4- in PBMC
alone (1.1 ± 0.6 % vs. 1.8 ± 0.9 %, p = 0.053) and in co-
culture (1.1 ± 0.7 % vs. 2.1 ± 0.7 %, p = 0.01); but there
was no difference in the percentage between PBMC
alone and co-culture (data not shown).
Actual IL-17 secretion in supernatants was mea-
sured by ELISA. Without PHA, IL-17 production was
undetectable in resting PBMC (Fig. 2b); but it was
present at a very low level in co-culture of PBMC
and synoviocytes (1.1 ± 2.2 pg/ml). TCR activation by
PHA did not increase significantly IL-17 secretion in
PBMC alone (Fig. 2b). In contrast, there was a significant
increased production of IL-17 in co-culture with activated
PBMC (1.1 ± 2.2 pg/ml vs. 185.5 ± 220.3 pg/ml, p = 0.002,
Fig. 2b). The activation of PBMC by anti-CD3 and anti-
CD28 gave similar results as PHA activation (data not
shown). These results demonstrated that the combination
of TCR activation and cell–cell contact was required to
obtain a high IL-17 secretion. Furthermore, TNF, which is
a major cytokine involved in RA pathogenesis, is known
to stimulate synoviocytes. Activation of synoviocytes by
TNF was tested in co-culture without TCR stimulation,
giving similar results than in the control condition (data
not shown).
To confirm the crucial role of cell–cell contact in IL-
17 production, the transwell system was used. This con-
tact inhibition had no effect on Th17 differentiation, as
the percentage of IL-17 positive cells was similar
Fig. 1 Effect of interaction between synoviocytes and PBMC on IL-6 and IL-1β production. Healthy PBMC were cultured alone or in co-culture
with RA synoviocytes at a 5:1 ratio for 48 h, in the presence or absence of PHA (5 μg/ml). The transwell system was used in co-cultures to inhibit
cell–cell contact. Production of IL-6 (a) and IL-1β (b) in cell supernatants was measured by ELISA. Each linked dot plot represents one experiment
in the different conditions. *Compares the culture conditions (PBMC alone, co-culture or transwell) with and without PHA. #Compares the activation
state (control or PHA) in the culture conditions. *#p≤ 0.05. IL interleukin, PBMC peripheral blood mononuclear cells, PHA phytohemagglutinin, RA
rheumatoid arthritis
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between co-culture and transwell system (2.1 ± 2.6 % vs.
2.1 ± 2.3 % without PHA; 4.3 ± 3.7 % vs. 2.8 ± 3.0 % with
PHA, Fig. 2a). Conversely, without cell interactions in the
PHA activation condition, IL-17 secretion was strongly re-
duced (265.0 ± 183.9 pg/ml vs. 30.5 ± 44.6 pg/ml, p =
0.008), reaching the same level as PBMC alone (30.5 ±
51.5 pg/ml vs. 26.3 ± 36.7 pg/ml, respectively, Fig. 2b). This
transwell experiment clearly demonstrated that direct cell
interactions between activated PBMC and RA synovio-
cytes were crucial for high levels of IL-17 secretion. Fur-
thermore, using fixed synoviocytes with live activated
PBMC induced IL-17 secretion at a similar level compared
to co-culture with nonfixed synoviocytes. Conversely, fixed
PBMC with live synoviocytes produced no IL-17 (Fig. 2c).
Co-culture between autologous cells also increases
pro-inflammatory cytokine production
The cell specificity of IL-17 production induced by cell
interactions between immune and mesenchymal cells
was studied by comparing different mesenchymal cell
types (synoviocytes and ASC) and endothelial cells
(HUVEC) in co-culture. As shown in Fig. 3a, with both
RA synoviocytes and ASC, interactions with PBMC in-
duced high IL-6 production and a high IL-17 secretion
in co-culture with activated PBMC (Fig. 3a). In contrast,
co-culture with HUVEC did not induce IL-6 and IL-17 pro-
duction (Fig. 3a). This indicated that specific interactions
between fibroblast-like cells and immune cells are critical
to induce high pro-inflammatory cytokine production.
To confirm that pro-inflammatory cytokine produc-
tion resulting from cell interactions may occur inside
the inflamed synovium, co-culture experiments with
synoviocytes and PBMC from the same RA patient were
tested. As observed in Fig. 3b, co-cultures with autolo-
gous cells gave similar results as co-cultures with RA
synoviocytes and healthy PBMC. This indicated the
absence of contribution of alloreactivity in the effect. In-
deed, cell interactions were sufficient to induce IL-6
(Fig. 3b). IL-17 was markedly more produced in co-
culture with autologous activated PBMC (Fig. 3b). In
parallel, co-cultures between PBMC from patient 1 and
synoviocytes from patient 2 and the other way around
were tested. Results were similar in both systems (Fig. 3b)
indicating the critical role of cell interactions in the pro-
inflammatory cytokine production.
Monocytes do not contribute to the high IL-17
production
Considering the role of IL-6 and IL-1β in the Th17 path-
way and the role of cell interactions in maintaining
Fig. 2 Effect of interaction between synoviocytes and PBMC on Th17 differentiation and IL-17 secretion. Healthy PBMC were cultured alone or in
co-culture with RA synoviocytes at a 5:1 ratio for 48 h, in the presence or absence of PHA (5 μg/ml). The transwell system was used in co-cultures
to inhibit cell–cell contact and fixed synoviocytes or fixed PBMC were used. PBMC were recovered after 48 h and stained for the surface markers
CD3 and CD4, and intracellular IL-17A. The percentage of CD3 + CD4 + IL-17A + is represented for each experiment (a). IL-17A production was
measured in supernatants after 48 h, by ELISA (b and c). Each linked dot plot represents one experiment in the different conditions. *Compares
the culture conditions (PBMC alone, co-culture or transwell) with and without PHA. #Compares the activation state (control or PHA) in the culture
conditions. *#p≤ 0.05. IL interleukin, PBMC peripheral blood mononuclear cells, PHA phytohemagglutinin, RA rheumatoid arthritis
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inflammation, the potential contribution of monocytes in
this loop was investigated. To study their involvement in
our co-culture system, monocytes were removed by ad-
herence. As IL-1β is mainly produced by monocytes in
PBMC, the reduction of IL-1β production can be consid-
ered as a good marker for the removal of monocytes. As
observed in Fig. 4a, the production of IL-1β was indeed
significantly inhibited in all conditions without monocytes
(p = 0.004). In contrast, IL-6 is a pro-inflammatory cyto-
kine produced by many cell types, including PBMC and
synoviocytes. In control condition, IL-6 secretion was sig-
nificantly decreased, but less than IL-1β, in culture of
PBMC alone and in co-culture without monocytes (10.3 ±
8.0 ng/ml vs. 3.4 ± 2.5 pg/ml, p = 0.003; 532.1 ± 217.5 ng/
ml vs. 431.7 ± 267.4 ng/ml, p = 0.01, respectively, Fig. 4b).
With PHA, removal of monocytes had an effect only in
PBMC alone (14.5 ± 6.1 ng/ml vs. 6.5 ± 2.3 ng/ml, p =
0.003, Fig. 4b). Surprisingly, IL-17 production was not af-
fected by removing monocytes (Fig. 4c). These results
showed that monocytes have no major role in the high IL-
17 secretion during cell interactions, indicating the in-
volvement of key interactions between lymphocytes and
mesenchymal cells.
To confirm the crucial role of synoviocytes and Th17
cells in the high IL-17 secretion, co-cultures between
synoviocytes and Th17 clones (ratio 1:1) were per-
formed. As observed in Fig. 4d, there was no IL-1β pro-
duction compared to co-cultures with PBMC. This
result was expected as the major source of IL-1β was
not present. In co-cultures with Th17 clones, IL-6 secre-
tion was induced in control condition as with PBMC,
even the level of production was lower than with PBMC
(90.2 ± 10.0 pg/ml vs. 712.1 ± 12.5 pg/ml), and with Th17
clones, PHA activation increased IL-6 secretion (635.6 ±
12.5 pg/ml vs. 90.2 ± 10.0 pg/ml, Fig. 4e). As with
PBMC, the detection of IL-17 production was possible
only with PHA activation (701.7 ± 39.1 pg/ml vs. 15.2 ±
0.2 pg/ml, Fig. 4f ) and the interaction with synoviocytes
largely increased this secretion (7013.0 ± 458.5 pg/ml vs.
701.7 ± 39.1 pg/ml, Fig. 4f ). These results confirmed the
crucial role of TCR activation and of cell–cell contact in
the high IL-17 production and make synoviocytes and
Th17 cells the two major cell types involved in this ele-
vated secretion.
Podoplanin plays a major role in high IL-17 secretion
during co-culture between activated PBMC and RA
synoviocytes
The role of direct physical cell interactions in the high IL-
17 production is critical. As podoplanin (pdpn) can be
Fig. 3 Confirmation in an autologous system and with other mesenchymal cell types. Healthy PBMC were cultured alone or in co-culture with RA
synoviocytes, ASC or HUVEC at a 5:1 ratio for 48 h, in the presence or absence of PHA (5 μg/ml). Levels of IL-17 and IL-6 were measured in the
supernatants after 48 h by ELISA (a). PBMC from RA patients were cultured alone or in co-culture with autologous synoviocytes or from other
patients, at the ratio 5:1 for 48 h, in the presence or absence of PHA (5 μg/ml). Levels of IL-17 and IL-6 were measured in the supernatants after
48 h by ELISA. Values are individual results (b). ASC adipose-derived stem cells, HUVEC human umbilical vein endothelial cells. IL interleukin, PBMC
peripheral blood mononuclear cells, PHA phytohemagglutinin, RA rheumatoid arthritis
Noack et al. Arthritis Research & Therapy  (2016) 18:148 Page 6 of 12
expressed by different cell types, including synoviocytes,
its potential role was studied with a blocking anti-pdpn
antibody. A dose–response curve was performed with dif-
ferent concentrations of anti-pdpn antibody (Ab), 0, 1, 5,
10 and 20 μg/ml, to determine the optimum concentra-
tion of anti-pdpn Ab. The concentration of 5 μg/ml of
antibody pre-incubated for 4 h gave the higher inhibition
of cytokine production (data not shown). In the co-culture
of synoviocytes and activated PBMC, the presence of anti-
pdpn Ab inhibited significantly IL-17 secretion by 64.9 ±
24.0 %. (p = 0.008, Fig. 5a and c), IL-1β secretion (45.3 ±
25.5 % of inhibition, p = 0.02, Fig. 5c), but not IL-6 secre-
tion (10.1 ± 9.0 % of inhibition, p = 0.25, Fig. 5c). More-
over, the effect of anti-pdpn antibody was specific as
results with a control antibody were similar than without
antibody (93.2 ± 31.4 pg/ml vs. 88.8 ± 29.9 pg/ml for IL-
17, Fig. 5a, data not shown for IL-1β and IL-6).
The inhibition of pdpn was tested by siRNA specific
for pdpn in synoviocytes. The presence of siPdpn inhib-
ited the IL-17 production by around 30 % (74.6 ± 7.0 vs.
109.3 ± 10.5 pg/ml, Fig. 5a). This effect was specific for
siPdpn as there was no inhibition of IL-17 secretion
with the mock and with siPPIB (103.2 ± 5.9 pg/ml and
112.5 ± 15.6 pg/ml vs. 109.3 ± 10.5 pg/ml, respectively,
data not shown). Furthermore, to verify the specificity
of the siRNA, the gene expression of pdpn and PPIB
was tested. In Fig. 5b, the expression of pdpn was inhib-
ited only with the siPdpn, but not with the siPPIB (posi-
tive control) neither with the mock (negative control).
The expression of PPIB was inhibited with the siPPIB
but not with the siPdpn neither with the mock. This
confirmed the specificity of the siPdpn.
Furthermore, with a therapeutic perspective in mind,
anti-pdpn Ab was tested in an autologous system. As
observed in Fig. 5d, the presence of anti-pdpn Ab
decreased IL-17 (76.0 ± 26.0 % of inhibition) and IL-1β
production (34.3 ± 26.2 % of inhibition), in a similar
percentage as in the heterologous system. IL-6 secretion
was not affected (Fig. 5d). These results in the autolo-
gous system supported the involvement of pdpn in the
high IL-17 secretion during cell interactions as seen in
vivo.
Pdpn has been shown to be expressed mainly by RA
synoviocytes. To study the regulation of its expression
during cell interactions, co-cultures were performed as de-
scribed before and after 48 h, cells (synoviocytes and
PBMC) were recovered and stained for pdpn. PBMC alone
showed a very low percentage of pdpn + cells (1.0 ± 0.8 %
Fig. 4 Role of monocytes on pro-inflammatory cytokine production. Healthy PBMC or Th17 clones were cultured alone or in co-culture with RA
synoviocytes at a 5:1 ratio or 1:1 ratio, respectively, for 48 h, in the presence or absence of PHA (5 μg/ml), and monocytes were removed or not
by adherence before culture. Production of IL-1β (a, d), IL-6 (b, e) and IL-17 (c, f) were measured in supernatants after 48 h, by ELISA. *Compared
conditions with and without monocytes. *p≤ 0.05. IL interleukin, PBMC peripheral blood mononuclear cells, PHA phytohemagglutinin, RA
rheumatoid arthritis
Noack et al. Arthritis Research & Therapy  (2016) 18:148 Page 7 of 12
without PHA; 0.8 ± 0.7 % with PHA, Fig. 6a and c).
As synoviocytes expressed pdpn, the side scatter was
focus more for PBMC. Interestingly, the percentage of
pdpn + cells increased in co-culture (11.2 ± 6.2 %
without PHA; 32.7 ± 8.1 % with PHA, p = 0.04, Fig. 6a
and c). This increase was present in different popula-
tions, CD3- (9.2 ± 2.2 % without PHA; 35.9 ± 0.5 %
with PHA); CD3 + CD4- (11.3 ± 3.7 % without PHA;
43.7 ± 7.2 % with PHA) and in CD3 + CD4+ (17.1 ±
5.1 % without PHA; 55.7 ± 1.5 % with PHA). Interest-
ingly, in CD3 + CD4+, co-culture increased the pdpn
expression in IL-17- (0.9 ± 0.6 % vs. 16.7 ± 5.0 % with-
out PHA; 3.3 ± 3.4 % vs. 54.3 ± 0.9 with PHA, Fig. 6b)
but this effect was major in IL-17+ cells (9.4 ± 1.1 %
vs. 69.7 ± 7.6 % without PHA; 8.4 ± 8.3 % vs. 85.7 ±
2.8 % with PHA). These results indicated that pdpn
expression could be regulated by cell–cell contact,
with an effect mainly in Th17 cells. These results
were also consistent with the increase of IL-17 secre-
tion associated with overexpression of pdpn in both
synoviocytes and activated PBMC. In addition, PBMC
showed an increased size in co-culture, especially with
PHA (data not shown), reflecting the high size with the
plasma cell morphology observed previously in IL-17+
cells under activation and in in vivo [3].
Discussion
Cell interactions between mesenchymal and immune
cells are known to induce the production of pro-
inflammatory cytokines and also to affect the survival of
both cell types [7, 20–22]. In the context of RA, a co-
culture system between RA synoviocytes and PBMC was
used to mimic the in vivo situation. Cell interactions
were sufficient to provide a necessary activation state for
the secretion of IL-6 and IL-1β and this is in agreement
with a previous study showing that MSC-PBMC interac-
tions increased IL-6 and IL-1β mRNA [7]. These obser-
vations reflect how high levels of pro-inflammatory
cytokines, including IL-6 and IL-1β, can be produced lo-
cally by the RA synovium [23]. Furthermore, co-culture
with autologous cells, PBMC and synoviocytes from the
same patient, validated our co-culture in vitro model
mimicking the in vivo inflammation.
IL-6 and IL-1β are known to be involved in Th17 cell
differentiation [16–18]. Th17 cells in turn secrete IL-17
which acts on synoviocytes, often in synergy with other cy-
tokines such as TNF-α, IL-1β or granulocyte-macrophage
colony-stimulating factor (GM-CSF) [2, 24–26]. Consider-
ing the results on IL-6 and IL-1β production, the effect
of cell interactions on the Th17 pathway was studied
to differentiate the intracellular expression from the
Fig. 5 The major role of podoplanin in the high IL-17 secretion. Healthy or RA PBMC were pre-incubated 4 h with or without human anti-pdpn
or irrelevant antibody before co-culture with synoviocytes or autologous synoviocytes, respectively, for 48 h, in the presence of PHA (5 μg/ml).
For siRNA, RA synoviocytes were transfected without (control) or with siRNA (pdpn, PPIB or mock) and then used in co-culture with healthy PBMC,
in the presence of PHA, during 48 h. Levels of IL-17, IL-1β and IL-6 were measured in the supernatants after 48 h by ELISA. The concentration of
IL-17 in the different conditions of culture is represented (a). The expression of the genes pdpn and PPIB compared to control (control = 1) (b) is
represented as well as the percentage of cytokine inhibition compared to control in the heterologous system (c) and in the autologous system
(d). *p≤ 0.05 compared to control. IL interleukin, PBMC peripheral blood mononuclear cells, PHA phytohemagglutinin, RA rheumatoid arthritis,
pdpn podoplanin, PPIB peptidylpropyl isomerase B, siRNA small interfering RNA
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secretion of IL-17. The percentage of CD3 + CD4 +
IL-17+ cells was evaluated in PBMC alone or in co-
culture. Cell contact alone had no major effect on
Th17 differentiation measured by intracellular stain-
ing. Only TCR activation had a modest effect. This
indicated that Th17 differentiation requires cell acti-
vation more than cell–cell contact.
When looking at the production of IL-17 and in con-
trast to that of IL-6 and IL-1β, cell interactions were not
sufficient to induce a high IL-17 secretion. Its produc-
tion required two signals, TCR activation and cell–cell
contact. Moreover, activation of synoviocytes by TNF
alone in co-culture without TCR stimulation had no ef-
fect on IL-17 production. In fact, IL-17 secretion during
cell interactions was dependent on T cell but not syno-
viocyte activation. Transwell experiments confirmed that
cell interactions were crucial to have an elevated IL-17
secretion even in the presence of TCR activation.
These results reveal a major discrepancy between
intracellular and secreted IL-17. The intracellular pres-
ence of IL-17 inside Th17 cells does not mean by itself a
high secretion of IL-17. The presence of Th17 cells even
with TCR activation was not enough to have the release
of high levels of IL-17. It was necessary that activated
cells could physically interact with mesenchymal cells,
derived from either synovium, bone marrow, or adipose
tissue. Thus, TCR activation and cell–cell contact are
two needed mechanisms leading to a high IL-17 produc-
tion and this differs from intracellular expression of IL-
17. Both mechanisms are present during RA pathogen-
esis [13, 27–30], and this could explain the presence of
IL-17 in the joints of RA patients [31, 32].
Furthermore, the secretion of IL-17 was variable
depending on experiments which used different donors
for PBMC and RA synoviocytes. This variability reflected
the heterogeneity which characterizes the RA population
Fig. 6 Expression of podoplanin in PBMC alone or in co-culture. Healthy PBMC were cultured alone or in co-culture with RA synoviocytes at a 5:1
ratio for 48 h, in the presence or absence of PHA (5 μg/ml). Cells were recovered after 48 h and stained for pdpn (a and c) or CD3, CD4, IL-17
and pdpn (b). Dot plot of one experiment is represented (a and b). The percentage of pdpn + cells in the different conditions is represented (c).
*p≤ 0.05. IL interleukin, PBMC peripheral blood mononuclear cells, PHA phytohemagglutinin, pdpn podoplanin, RA rheumatoid arthritis
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suggesting the variable contribution of IL-17 in the
inflammatory process. The variability in IL-17 secretion
observed in our experiments could explain in part the
heterogeneity of the response to an anti-IL-17 treatment
in RA patients [33, 34]. Such heterogeneity remains to
be explained. One explanation could be the contribution
of gene polymorphisms in the regulation of the Th17
pathway. IL4R gene polymorphisms have been associated
with RA severity by increasing the Th17 cell frequency
and by modulating the inhibitory effect of IL-4 on Th17
development [35] and the modulation of IL-17 produc-
tion [36]. IL-23R polymorphisms have been implicated
in IL-17A expression in RA [37].
The critical contribution of interactions between im-
mune cells and mesenchymal cells indicated the need to
identify a molecular mechanism. The limited contribu-
tion of monocytes suggested a molecule present on lym-
phocytes or on mesenchymal cells or on both. Pdpn,
which is a type I transmembrane protein, appeared as a
good candidate. Pdpn-mediated interaction of RA syno-
viocytes and platelets modulates IL-8 production [8].
Furthermore, in the SKG spontaneously occurring arth-
ritis model, pdpn is upregulated in Th17 cells compared
to other Th cell subsets [9] and in the synovium of RA
patients [11]. In a mouse model of multiple sclerosis,
mice treated with anti-pdpn present a delayed onset of
symptoms [10]. Based on these observations, an anti-
body against pdpn was used in the co-culture system
and siRNA specific for pdpn was used on synoviocytes.
Both means induced an inhibition of IL-17 production
and confirmed the role of pdpn in the IL-17 secretion.
These results focused on the podoplanin expressed by
RA synoviocytes but it was known that Th17 cells could
express pdpn, notably in an experimental arthritis model
and in clinical RA [38, 39]. In accordance with this, the
three different tested protocols, the pre-incubation of
PBMC, the pre-incubation of synoviocytes or the pre-
incubation of both cells, gave similar results (data not
shown). Acting first on synoviocytes or PBMC did not
affect the inhibitory effect of the anti-pdpn. This is in
line with the expression of pdpn by Th17 cells and the
fact that the effect of anti-pdpn could be both direct on
Th17 cells and indirect by acting on synoviocytes to
inhibit the IL-17 production during cell interactions. In
addition, the lower percentage of inhibition obtained
with siPdpn compared with the anti-pdpn Ab could also
indicate the respective involvement of pdpn expressed
by synoviocytes and by Th17 cells. The regulation of
pdpn in PBMC and specifically in Th17 cells remains to
be clarified.
The interaction between pdpn and its receptor could
occur in the two directions, from synoviocytes to PBMC,
or from PBMC to synoviocytes. The receptor of pdpn
CLEC-2 is known to be mainly expressed by platelets
[40] and also by mature dendritic cells or peripheral
blood B lymphocytes [41–44]. Its expression in our co-
culture system could be studied to provide a new insight
on the pathway by which pdpn could influence the IL-17
secretion. Currently, there is no evidence for its expres-
sion on Th17 cells and this could also suggest a possible
new receptor for pdpn. A recent study has shown that
pdpn can negatively regulate CD4+ effector T cell func-
tions through pdpn-CLEC-2 interaction [45]. A high
pdpn expression was found on “nonpathogenic” Th17
lymphocytes while “pathogenic” Th17 cells expressed
less pdpn. Thus, pdpn displays two divergent functions
which may depend on different ligands. One ligand, such
as CLEC-2 could mediate T cell inhibition while another
ligand could promote inflammation by stimulating pro-
inflammatory cytokine production. Furthermore, our
results demonstrated that the inhibition of the inter-
action mediated by pdpn decreased at least by 50 % the
secretion of IL-17 and of IL-1β, but not that of IL-6.
Furthermore, in both PBMC and synoviocytes, pdpn ex-
pression was increased in co-culture with TCR activation
which correlates with the high IL-17 production. These
results suggested that cell interactions of synoviocytes
with activated immune cells increased pdpn expression
that contributed to the high IL-17 secretion.
If podoplanin seems to be a good potential therapeutic
target, investigating the effect of cell interactions on
other signaling molecules involved in Th17 differenti-
ation and function could be interesting. Indeed, the
interaction with mesenchymal stem cells (MSC) could
on the one hand enhance Th17 activity [7, 46] but on
the other hand it could repress Th17 molecular program
through PD-1 [47]. Furthermore, IL-17A can induce sol-
uble PD-1 (sPD-1) which level is increased in RA serum.
This overexpression of sPD-1 might block the inhibitory
PD-1 pathway [48]. Investigating the PD-1 pathway in
co-culture system could allow identifying another
mechanism. Signaling lymphocytic activation molecule
(SLAM) is another candidate as it promotes the differen-
tiation of IL-17-secreting effectors [49]. Inducible T cell
costimulator (ICOS) signaling, which belongs to the
CD28 costimulatory molecule superfamily, has been also
shown to play a critical role in the generation and main-
tenance of human Th17 cells [50] and it could be
another candidate.
Conclusions
This study showed that cell interactions between
fibroblast-like mesenchymal cells and immune cells play
a major role in pro-inflammatory cytokine production,
leading to a major increase in IL-17 secretion distinct
from intracellular expression. The interaction molecule
podoplanin appears to have a large contribution to the
high IL-17 secretion that in turn may contribute to the
Noack et al. Arthritis Research & Therapy  (2016) 18:148 Page 10 of 12
chronicity of inflammation. In this context, pdpn could
be a potential therapeutic target to block Th17 cell activ-
ity during chronic inflammation.
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